What the FDA labels say about taking them together
Medroxyprogesterone and progesterone
Medroxyprogesterone's FDA label (Depo-Provera) of August 25, 2026 names progesterone in its drug interactions section, and progesterone's label names medroxyprogesterone too. The medroxyprogesterone label: “The following laboratory tests may be affected by progestins including Depo-Provera CI: (a) Plasma and urinary steroid levels are decreased. (b) Gonadotropin levels are decreased. …”
Check it at the source: the medroxyprogesterone FDA label on DailyMed (effective June 29, 2026, Pharmacia & Upjohn Company LLC); the progesterone FDA label on DailyMed (effective July 23, 2026, Acertis Pharmaceuticals, LLC).
What does the medroxyprogesterone label say about progesterone?
Depo-Provera label (Pharmacia & Upjohn Company LLC, August 25, 2026), drug interactionsThe following laboratory tests may be affected by progestins including Depo-Provera CI: (a) Plasma and urinary steroid levels are decreased (e.g., progesterone, estradiol, pregnanediol, testosterone, cortisol). (b) Gonadotropin levels are decreased. (c) Sex-hormone-binding-globulin concentrations are decreased. (d) Protein-bound iodine and butanol extractable protein-bound iodine may increase.
Source: FDA drug label (Depo-Provera, NDA020246), Pharmacia & Upjohn Company LLC, effective August 25, 2026 (SPL set 199cf13e-0859-4a73-9b45-e700d0cd1049), via openFDA
Source: FDA drug label (Provera), NDA011839 (Pfizer), as published by Pharmacia & Upjohn Company LLC, effective June 29, 2026 (SPL set a586be28-96af-4fed-a13f-9b94fd4c7405), via openFDA; the full label on DailyMed
What does the progesterone label say about medroxyprogesterone?
Progesterone label, warningsThe safety and efficacy of estrogen plus progestogen for the prevention of cardiovascular disorders has not been established. (See CLINICAL STUDIES ) The Women’s Health Initiative (WHI) estrogen plus progestin trial reported increased risks of PE, DVT, stroke, and MI in postmenopausal women (50 to 79 years of age, average age 63.4 years) during 5.6 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg] combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo.
Source: FDA drug label (Prometrium), Acertis Pharmaceuticals, LLC, effective July 23, 2026 (SPL set 1cf237ff-c4f8-4faa-a7aa-77599c856889), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Medroxyprogesterone | Progesterone | |
|---|---|---|
| Labeled for | Birth control, Pain | n/a |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $22.85 per mL 150 mg/mL | $0.229 per capsule 100 mg capsule |
| Shortage now | A presentation being discontinued | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once